Pacira Biosciences Inc (PCRX) financials
Pacira Biosciences revenue and earnings by year
Pacira Biosciences's revenue was $726 million in the fiscal year to December 31, 2025, up 3.6% from the year before. Net income was $7.03 million, 1.0% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 11.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726 | 701 | 675 | 667 | 542 | 430 | 421 | 337 | 287 | 276 |
| Revenue growth | 3.6% | 3.9% | 1.2% | 23.1% | 26.0% | 2.0% | 24.8% | 17.7% | 3.7% | — |
| Gross profit | 577 | 531 | 490 | 468 | 401 | 312 | 314 | 250 | 199 | 166 |
| Gross margin | 79.4% | 75.7% | 72.6% | 70.1% | 74.1% | 72.7% | 74.7% | 74.3% | 69.3% | 60.2% |
| Operating income | 19 | -73 | 88 | 60 | 90 | 46 | 10 | 16 | -25 | -32 |
| Operating margin | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.7% | -8.7% | -11.6% |
| Net income | 7 | -100 | 42 | 16 | 42 | 146 | -11 | -0 | -43 | -38 |
| Net margin | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -14.9% | -13.7% |
| Diluted EPS | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 | $3.28 | -$0.28 | -$0.02 | -$1.08 | -$1.02 |
| Free cash flow | 137 | 179 | 139 | 115 | 80 | 39 | 60 | 34 | -1 | 9 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PCRX in Markets.
How Pacira Biosciences makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| EXPAREL | $148M | 76.8% |
| ZILRETTA | $32.6M | 17.0% |
| Iovera | $6.81M | 3.5% |
| Bupivacaine Liposome Injectable Suspension | $3.22M | 1.7% |
| Royalty | $1.91M | 1.0% |
See also: PCRX valuation and P/E history · PCRX returns
No forecast, no recommendation. This page describes Pacira Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.